아주대학교 약학박사(2017)
고려대학교 이학석사(2005)
고려대학교 이학학사(2003)

現) 국민대학교 응용화학부 바이오의약학과 부교수
現) (사)의약품제조혁신학회 사무국장
前) 대구가톨대학교 제약공학과 조교수
前) (주)유한양행 중앙연구소 수석연구원
現) 국가신약개발사업단 기획/자문위원
現) 식품의약품안전처 기획/평가/자문위촉위원
現) 산업통상자원부 기획/자문위원
現) 보건산업진흥원 기획/자문/평가위원
現) (사)대한약학회 산업약학분과 학술위원
現) (사)한국약제학회 편집간사
現) Journal of pharmaceutical investigation, Associate editor

1. 인공지능 의약품설계 및 제조공정 플랫폼
2. GLP-1경구제 개발, 인슐린경구제, 인공혈액
3. QbD/PAT, 연속생산, IND, NDA(CTD)

대표특허: 세마글루티드 및 흡수촉진제를 유효성분으로 포함하는 경구투여용 제제 및 이의 제조방법(특허번호:10-2024-0141439)
대표논문
1. Perfluorocarbon-based artificial oxygen carriers for red blood cell substitutes: considerations and direction of technology
Journal of Pharmaceutical Investigation(10, 1007)2024.02교신저자2093-6214,IF, 5.5(Springer)
2. Application of continuous manufacturing for solid oral dosage forms, Journal of Pharmaceutical Investigation(53, 457-474)2023.07
교신저자2093-6214, IF, 5.5, 2회 인용(Springer)
3. The Development and Validation of Simultaneous Quantitative Analysis Reversed-phase High-performance Liquid Chromatography for Sitagliptin Phosphate Monohydrate and Dapagliflozin Propanediol Monohydrate Fixed-dose Combination Dual-layered Tablet
Current Pharmaceutical Analysis(19(5), 423-431), 2023.06, 교신저자, 1573-4129(Bentham science)
4. Development of Clinically Optimized Sitagliptin and Dapagliflozin Complex Tablets: Pre-Formulation, Formulation, and Human Bioequivalence Studies, Pharmaceuticals,(15(4), 1246),2023.04,교신저자,1999-4923, IF 5.4(MDPI)
5. Design of experiment (DoE)-based formulation design of bepotastine sustained-release tablet and in vitro-in vivo pharmacokinetic correlation, Journal of Pharmaceutical Investigation, 2023-01, 교신저자, 2093-6214, IF 5.5(Springer)
6. Quality by Design (QbD) application for the pharmaceutical development process, Journal of Pharmaceutical Investigation(52, 649-682)2022.11, 교신저자,2093-6214, IF 5.5 (Springer)
7. Development of Nafamostat Mesylate Immediate-Release Tablet by Drug Repositioning Using Quality-by-Design Approach, Pharmaceuticals(14(6), 1219), 2022.06, 교신저자, 1999-4923, IF 6.321(MDPI)
8. In Vitro-In Vivo Correlation of Tianeptine Sodium Sustained-Release Dual-Layer Tablets, Molecules(27(9), 2828), 2022.04, 교신저자, 1420-3049, IF, 4.927(MDPI)
9. Studies on Preformulation and Formulation of JIN-001 Liquidsolid Tablet with Enhanced Solubility, Pharmaceuticals(15(4), 412)2022.03, 교신저자, 1999-4923, IF 6.321(MDPI)
10. QbD Consideration for Developing a Double-Layered Tablet into a Single-Layered Tablet with Telmisartan and Amlodipine, Pharmaceutics(14(2), 377)2022.02 주저자(제1저자)1999-4923, IF 6.321
11. Hyaluronan Self-Agglomerating Nanoparticles For NonSmall Cell Lung Cancer Targeting, Cancer Nanotechnology, 2021.10, 주저자(제1저자)1868-6958, IF 5.095
12. 제약산업학(개정판3판), PharmaceuticalIndusrty: from Bench to Market, fromMarket to Bench, 신일북스, 2021, Chapter저자, 9791186830048
13. Analysis of Perception and Status Survey on the Introduction of QbD System by Pharmaceutical Companies in Korea, 약학회지(4, 301)2021.08, 교신저자,0377-9556, KCI IF, 0.14
14. Development and Validation of a Reversed-phase High Performance Liquid Chromatography Method for the Simultaneous Estimation of Rosuvastatin Calcium and Telmisartan in Fixed-Dose Complex Dual-Layer Tablets in Six Dosage Forms, Indian Journal of Pharmaceutical Sciences,(3, 451),2021.06,교신저자,0250-474X,IF 0.975
15. Development of an Analysis System to Support the Determination of Whether to Separate the Evaluation of Majors and Non-Major ,한국정보기술학회논문지, 2021.05, 공동저자, 1598-8619, KCI IF, 0.47
16. Quality by Design Applied Development of Immediate-Release Rabeprazole Sodium Dry-Coated Tablet, Pharmaceutics (13(2), 259)2021.02, 교신저자,1999-4923,IF 6.321
17. Nanoporous Silica Entrapped Lipid-Drug Complexes for the Solubilization and Absorption Enhancement of Poorly Soluble Drugs, Pharmaceutics (13(1), 63)2021.01, 교신저자, 1999-4923, IF 6.321
18. Nanotechnology in the arena of cancer immunotherapy, Archives of pharmacal research, 2020.01, 공동저자, 0253-6269, IF 4.946
19. 설계기반품질고도화(QbD)의약품 개발을 위한 오픈소스 기반 실험설계 R 프로그램의 활용, 약학회지(5, 274), 2019.10, 교신저자,0377-9556(KCI IF, 0.14)
20. Transformer-ethosomes with palmitoyl pentapeptide for improved transdermal delivery, JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY(52, 460)2019.08, 주저자(제1저자), 1773-2247,(IF 3.981)
21. Preparation of Silica Microparticles as Volatile Material Carrier and Their Sustained-Release Property,JOURNAL OF NANOSCIENCE AND NANOTECHNOLOGY,(19, 1188), 2019.02,공동저자, 1533-4880, (IF 1.354)
22. Quality-by-design approach for the development of telmisartan potassium tablets, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY(44, 837),2018.06,교신저자, 0363-9045(IF, 2.295)
23. Development of stabilized tenofovir disoproxil tablet: degradation profile, stabilization, and bioequivalence in beagle dogs, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY,(44, 757), 2018.05, 공동저자,0363-9045(IF 2.295)
24. Improved Antitumor Efficacy of Hyaluronic Acid-Complexed Paclitaxel Nanoemulsions in Treating Non-Small Cell Lung Cancer, BIOMOLECULES THERAPEUTICS(25, 411),2017.07,주저자(제1저자),1976-9148(IF 4.634)
25. High paclitaxel-loaded and tumor cell-targeting hyaluronan-coated nanoemulsions, COLLOIDS AND SURFACES B-BIOINTERFACES
(150, 362)2017.02, 주저자(제1저자)0927-7765(IF 5.268)
26. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer, INTERNATIONAL JOURNAL OF NANOMEDICINE(12, 645)2017.01주저자(제1저자)1178-2013(IF 6.4)

1. 국책연구과제 현재 6건 수행 중(국가연구비 XXX억: 산업통상자원부, 식품의약품안전처)
2. 기업연구용역 20여건 수행 (총 XX억: (주)대웅제약 외 7개 기업 )
3. 제약기업 기술이전 21건 (IND 및 NDA포함): 출품 8건

● 용출기(8구)2대, 용출기(12구)3대, HPLC 7대

● 로터리타정기 2대, 피츠밀, 오실레이터

● 습식과립기 2대, 코팅기 1대, IPC장비 8종, LOD 등

● Microfluidizer

● Nano입도제타측정기

● 산소측정기, DSC, FT-IR 등

QbD, GLP-1 경구제, 산업약학, 연속공정, PAT, 인공지능, 의약품설계, AI플랫폼